Tirz. 5 mg

5mg Tirzeptatide

Adapt Peptides offers Tirz 5mg for sale with unmatched purity and reliability. Buy 5mg Tirz vials in lyophilized powder form, each manufactured to research-grade standards. Each batch undergoes rigorous third-party analysis to verify over 99.6% purity and activity. Order tirzepatide 5mg now for fast, secure shipping and responsive US-based customer support.

What is Tirzepatide?

Tirzepatide is a synthetic research peptide classified as a dual receptor agonist, acting on both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

This dual action distinguishes it from earlier GLP-1–only compounds, as it may activate multiple hormonal pathways that influence energy metabolism, insulin regulation, and appetite control. It’s also different from triple agonists such as retatrutide.

Preclinical investigations have highlighted Tirzepatide’s capacity to mimic and amplify the activity of two endogenous incretin hormones—GLP-1 and GIP. These gut-derived hormones are secreted in response to nutrient intake and are central to stimulating insulin release, lowering glucagon secretion, delaying gastric emptying, and modulating satiety.

Adapt Peptides supplies Tirzepatide as a high-purity lyophilized powder, intended for reconstitution under sterile laboratory conditions. All material is verified through independent testing to confirm peptide identity and purity.

Mechanism of Action (Based on Research)

Tirzepatide acts as a dual agonist of the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, both of which are integral to the incretin system[1].

Incretins are gut hormones, (GLP-1) and gastric inhibitory polypeptide (GIP), released after eating to boost insulin secretion, reduce glucagon (a hormone that raises blood sugar), slow digestion, and increase satiety

These hormones play critical roles in modulating insulin secretion, regulating blood sugar, and influencing appetite signals[2].

By simultaneously activating GLP-1 and GIP receptors, Tirzepatide engages complementary pathways that support metabolic balance. This dual targeting sets it apart as a valuable research tool for studies on energy regulation and glucose control.

GLP-1 and GIP Activation

In laboratory settings, GLP-1 receptor stimulation has been shown to boost insulin release, suppress glucagon secretion, and delay gastric emptying. These mechanisms help stabilize post-meal glucose levels[3].

Although historically less emphasized, GIP receptor activation also contributes to insulin sensitivity and lipid metabolism[4].

When both incretin pathways are stimulated in tandem, as with Tirzepatide, early research suggests the combined effect may surpass the impact of GLP-1 agonism alone[5]. This has been linked to improved glucose control and appetite regulation in preclinical models.

Additionally, studies indicate that this dual activity can influence central nervous system pathways involved in satiety while also affecting peripheral processes tied to lipid storage and energy expenditure[6].

These mechanisms are still being investigated, but existing data suggests that Tirzepatide’s multi-receptor engagement may provide broader insights into obesity, insulin resistance, and related metabolic disorders compared to single-pathway compounds.

Tirzepatide Research Applications

Tirzepatide has gained significant attention in preclinical and laboratory research for its role in metabolic function. It has been examined in studies of obesity, insulin signaling, and overall energy expenditure.

Although not approved for medical use, data from animal and in vitro studies indicate that Tirzepatide’s dual-agonist profile may offer advantages over GLP-1–only analogs.

Obesity Management

In diet-induced obesity models, Tirzepatide has been associated with notable reductions in body weight[8]. These effects appear to stem from multiple mechanisms, including appetite suppression, slower gastric emptying, and enhanced energy expenditure, likely influenced by both central and peripheral hormonal signaling.

Unlike GLP-1–only agonists, some findings suggest Tirzepatide may better preserve baseline energy levels, potentially reducing fatigue that can arise with long-term use of single-pathway incretin mimetics [9].

Note: Some reports, including anecdotal feedback and early observational data, describe mild fatigue or reduced energy in certain research contexts. This variability may reflect differences in study design, dosing, or individual response.

Metabolic Syndrome Research

Tirzepatide has also been explored as a model compound for metabolic syndrome—a group of interrelated conditions such as high blood pressure, abnormal lipid levels, central obesity, and insulin resistance.

In preclinical trials, the peptide has demonstrated the ability to enhance insulin sensitivity, improve glucose utilization, and lower markers of systemic inflammation[10]. Its dual mechanism may allow for broader modeling of metabolic improvements compared to GLP-1 receptor activation alone.

Diabetes Model Research

Several rodent studies investigating Tirzepatide in type 2 diabetes models have shown favorable outcomes, including better glucose tolerance, lower HbA1c, and preserved pancreatic beta-cell activity[11].

Activation of the GIP receptor complements GLP-1’s actions by enhancing glucose-dependent insulin secretion, which may reduce the risk of hypoglycemia in certain research settings. Preclinical findings also suggest potential protective effects on pancreatic islet architecture under prolonged metabolic stress.

Disclaimer: Tirzepatide is not approved for human consumption or therapeutic use. All references to biological effects are based solely on controlled laboratory and preclinical research. This compound is intended strictly for scientific investigation by qualified professionals.

Tirzepatide Peptide Characteristics

• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• CAS Number: 2023788-19-2
• Amino Acid Sequence: 39–residue linear peptide conjugated to a C20 fatty diacid chain (complete sequence has proprietary modifications to extend half-life and enhance receptor binding)
• Synonyms: LY3298176, dual GIP/GLP-1 receptor agonist, tirzepatide acetate (research form)
• Molar Mass: ~4,813.5 Da (may vary slightly depending on salt composition)
• Storage Guidelines:
  • Store lyophilized powder at room temperature: 68–86°F (20–30°C).
  • Routine storage: keep lyophilized peptide at 36–46°F (2–8°C) in a sealed, moisture-free container.
  • Long-term storage (months to 1–2 years): maintain below 32°F (0°C).
  • Do not freeze reconstituted solutions, as this may compromise peptide stability.
  • After reconstitution, store at 36–46°F (2–8°C) and use promptly.
  • Avoid repeated freeze–thaw cycles.

Note: Tirzepatide is supplied strictly for laboratory research. It is not approved for human use or therapeutic applications.

Tirzepatide vs. Semaglutide vs. Retatrutide (Comparison)

Safety and Side Effects in Research

Findings on Tirzepatide’s safety profile to date are largely based on animal studies, in vitro work, and early-phase clinical research. Within these contexts, Tirzepatide has demonstrated a generally well-tolerated profile, particularly at doses commonly used in controlled research.

Across multiple preclinical models, adverse reactions have been limited and often species- or dose-dependent. While most results suggest good tolerance, outcomes can vary depending on model organism, protocol design, and experimental conditions.

It is essential to emphasize that the absence of severe side effects in laboratory settings does not imply safety in humans.

Disclaimer: Tirzepatide is provided solely for scientific and laboratory research. It is not intended for human consumption, diagnostic purposes, or therapeutic use.

Certificate of Analysis (COA)

Every vial of Tirzepatide from Adapt Peptides is accompanied by a Certificate of Analysis (COA) verifying peptide identity, purity, and molecular structure. Each production lot is subjected to independent third-party testing, with purity levels consistently above 99.6%.

Researchers may request a COA at the time of purchase or download the batch CoA at the product page. This gives you confidence in data integrity and reproducibility during experimental use.

Tirzepatide FAQs

1. What is Tirzepatide used for in research?

Tirzepatide is examined for its activity at both GLP-1 and GIP receptors, which play central roles in glucose regulation, appetite control, and energy metabolism. Laboratory studies focus on its effects in models of insulin sensitivity, weight regulation, and metabolic function.

Is Tirzepatide the same as GLP-1 agonists like semaglutide?

Not exactly. Both compounds target GLP-1 receptors, but Tirzepatide also activates the GIP receptor, making it a dual agonist. This dual action may amplify its effects on insulin signaling and appetite pathways compared to GLP-1–only peptides.

What’s the difference between Tirzepatide and Retatrutide?

Tirzepatide functions as a dual GIP/GLP-1 agonist, while Retatrutide adds a third target—the glucagon receptor. Because of this, Retatrutide may also affect energy expenditure and fat metabolism, though research is still in early stages.

How is Tirzepatide stored for research?

Lyophilized Tirzepatide should be stored in a cool, dry environment at approximately –4°F (–20°C) for long-term stability.

For short-term storage, it may be kept at 36–46°F (2–8°C) in a sealed container.

Once reconstituted, the peptide should be refrigerated (36–46°F / 2–8°C) and used promptly in accordance with laboratory protocols.

Avoid repeated freeze–thaw cycles to preserve peptide integrity.

Scientific References

1. Fisman, E.Z., Tenenbaum, A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol 20, 225 (2021).

https://www.tandfonline.com/doi/full/10.1080/17512433.2024.2408753#graphical-abstract 

2. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008 Dec;60(4):470-512.

https://pmc.ncbi.nlm.nih.gov/articles/PMC2696340/ 

3. Zheng, Z., Zong, Y., Ma, Y. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024).

https://www.nature.com/articles/s41392-024-01931-z 

4. Kagdi S, Lyons SA, Beaudry JL. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. J Endocrinol. 2024 Apr 27;261(3):e230361.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11103678/ 

5. Kaneko S. Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. touchREV Endocrinol. 2022 Jun;18(1):10-19. https://pmc.ncbi.nlm.nih.gov/articles/PMC9354517/ 

6. Corrao S, Pollicino C, Maggio D, Torres A, Argano C. Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence. Front Endocrinol (Lausanne). 2024 Jun 24;15:1402583.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11228148/ 

7. Jensen TL, Brønden A, Karstoft K, Sonne DP, Christensen MB. The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects. Patient Prefer Adherence. 2024 Feb 8;18:373-382.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10861994/

9. Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, Mather KJ, Karanikas CA, Dunn J, Haupt A, Milicevic Z, Coskun T. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 2023 May 1;46(5):998-1004.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10154650/ 

10. Dutta P, Kumar Y, Babu AT, Giri Ravindran S, Salam A, Rai B, Baskar A, Dhawan A, Jomy M. Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond. Cureus. 2023 May 1;15(5):e38379.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10231274/ 

11. Yang J, Gu Y, Chen H, Wang H, Hong L, Li B, Yang L. Tirzepatide’s innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health. Front Pharmacol. 2024 Aug 28;15:1453825.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11387164/